305 related articles for article (PubMed ID: 22498430)
1. Novel therapeutic strategies targeting HIV integrase.
Quashie PK; Sloan RD; Wainberg MA
BMC Med; 2012 Apr; 10():34. PubMed ID: 22498430
[TBL] [Abstract][Full Text] [Related]
2. In search of second-generation HIV integrase inhibitors: targeting integration beyond strand transfer.
Voet AR; Maeyer MD; Debyser Z; Christ F
Future Med Chem; 2009 Oct; 1(7):1259-74. PubMed ID: 21426102
[TBL] [Abstract][Full Text] [Related]
3. Structure Based Drug Design: Clinically Relevant HIV-1 Integrase Inhibitors.
Kaur M; Rawal RK; Rath G; Goyal AK
Curr Top Med Chem; 2018; 18(31):2664-2680. PubMed ID: 30659539
[TBL] [Abstract][Full Text] [Related]
4. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
5. The future of integrase inhibitors of HIV-1.
Malet I; Calvez V; Marcelin AG
Curr Opin Virol; 2012 Oct; 2(5):580-7. PubMed ID: 22980926
[TBL] [Abstract][Full Text] [Related]
6. Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.
Engelman AN
J Biol Chem; 2019 Oct; 294(41):15137-15157. PubMed ID: 31467082
[TBL] [Abstract][Full Text] [Related]
7. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.
Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y
Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
Johnson BC; Métifiot M; Pommier Y; Hughes SH
Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850
[TBL] [Abstract][Full Text] [Related]
9. Targeting Integrase Enzyme: A Therapeutic Approach to Combat HIV Resistance.
Komal D; Khushboo J; Aaftaab S; Lakshmi S; Mallika A
Mini Rev Med Chem; 2020; 20(3):219-238. PubMed ID: 31613727
[TBL] [Abstract][Full Text] [Related]
10. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
11. Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence.
Mesplède T; Wainberg MA
Viruses; 2015 Jul; 7(7):3703-18. PubMed ID: 26198244
[TBL] [Abstract][Full Text] [Related]
12. Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond.
Beare KD; Coster MJ; Rutledge PJ
Curr Med Chem; 2012; 19(8):1177-92. PubMed ID: 22214459
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors.
Koneru PC; Francis AC; Deng N; Rebensburg SV; Hoyte AC; Lindenberger J; Adu-Ampratwum D; Larue RC; Wempe MF; Engelman AN; Lyumkis D; Fuchs JR; Levy RM; Melikyan GB; Kvaratskhelia M
Elife; 2019 May; 8():. PubMed ID: 31120420
[TBL] [Abstract][Full Text] [Related]
14. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
[TBL] [Abstract][Full Text] [Related]
15. Targeting HIV-1 integrase with strand transfer inhibitors.
Li Y; Xuan S; Feng Y; Yan A
Drug Discov Today; 2015 Apr; 20(4):435-49. PubMed ID: 25486307
[TBL] [Abstract][Full Text] [Related]
16. HIV integrase inhibitors: 20-year landmark and challenges.
Métifiot M; Marchand C; Pommier Y
Adv Pharmacol; 2013; 67():75-105. PubMed ID: 23885999
[TBL] [Abstract][Full Text] [Related]
17. The inhibition process of HIV-1 integrase by diketoacids molecules: Understanding the factors governing the better efficiency of dolutegravir.
El Khoury L; Piquemal JP; Fermandjian S; Maroun RG; Gresh N; Hobaika Z
Biochem Biophys Res Commun; 2017 Jul; 488(3):433-438. PubMed ID: 28478035
[TBL] [Abstract][Full Text] [Related]
18. Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase.
Zhang D; Debnath B; Yu S; Sanchez TW; Christ F; Liu Y; Debyser Z; Neamati N; Zhao G
Bioorg Med Chem; 2014 Oct; 22(19):5446-53. PubMed ID: 25150089
[TBL] [Abstract][Full Text] [Related]
19. New first and second generation inhibitors of human immunodeficiency virus-1 integrase.
Pendri A; Meanwell NA; Peese KM; Walker MA
Expert Opin Ther Pat; 2011 Aug; 21(8):1173-89. PubMed ID: 21599420
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
Shah BM; Schafer JJ; Desimone JA
Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
